
THURSDAY, Sept. 8, 2022 (HealthDay News) – In a rare second review, a U.S. Food and Drug Administration panel on Wednesday recommended approval for an experimental drug for ALS (amyotrophic lateral sclerosis). The FDA is not obligated to follow its advisors’ recommendations, though it usually does. Wednesday’s vote was 7-2 for approval. The same panel… read on > read on >